66 related articles for article (PubMed ID: 24416997)
41. FGFR4 prevents hyperlipidemia and insulin resistance but underlies high-fat diet induced fatty liver.
Huang X; Yang C; Luo Y; Jin C; Wang F; McKeehan WL
Diabetes; 2007 Oct; 56(10):2501-10. PubMed ID: 17664243
[TBL] [Abstract][Full Text] [Related]
42. Fibroblast growth factor receptor 4 regulates proliferation and antiapoptosis during gastric cancer progression.
Ye YW; Zhou Y; Yuan L; Wang CM; Du CY; Zhou XY; Zheng BQ; Cao X; Sun MH; Fu H; Shi YQ
Cancer; 2011 Dec; 117(23):5304-13. PubMed ID: 21567388
[TBL] [Abstract][Full Text] [Related]
43. FGFR4 overexpression in pancreatic cancer is mediated by an intronic enhancer activated by HNF1alpha.
Shah RN; Ibbitt JC; Alitalo K; Hurst HC
Oncogene; 2002 Nov; 21(54):8251-61. PubMed ID: 12447688
[TBL] [Abstract][Full Text] [Related]
44. Association between fibroblast growth factor receptor 4 polymorphisms and risk of hepatocellular carcinoma.
Yang Y; Zhou Y; Lu M; An Y; Li R; Chen Y; Lu DR; Jin L; Zhou WP; Qian J; Wang HY
Mol Carcinog; 2012 Jul; 51(7):515-21. PubMed ID: 21656577
[TBL] [Abstract][Full Text] [Related]
45. Expression and glycosylation studies of human FGF receptor 4.
Tuominen H; Heikinheimo P; Loo BM; Kataja K; Oker-Blom C; Uutela M; Jalkanen M; Goldman A
Protein Expr Purif; 2001 Mar; 21(2):275-85. PubMed ID: 11237689
[TBL] [Abstract][Full Text] [Related]
46. Retraction Notice to: The Cancer-Associated FGFR4-G388R Polymorphism Enhances Pancreatic Insulin Secretion and Modifies the Risk of Diabetes.
Ezzat S; Zheng L; Florez JC; Stefan N; Mayr T; Hliang MM; Jablonski K; Harden M; Stanĉáková A; Laakso M; Haring HU; Ullrich A; Asa SL
Cell Metab; 2020 Oct; 32(4):691. PubMed ID: 33027678
[No Abstract] [Full Text] [Related]
47.
Akdeniz Odemis D; Tuncer SB; Adamnejad Ghafour A; Jabbarli K; Gider Y; Celik B; Kuru Turkcan G; Sukruoglu Erdogan O; Kilic Erciyas S; Avsar M; Kebudi R; Buyukkapu Bay S; Tuncer S; Yazici H
J Oncol; 2020; 2020():9401038. PubMed ID: 33456465
[TBL] [Abstract][Full Text] [Related]
48. Recent developments in receptor tyrosine kinases targeted anticancer therapy.
Raval SH; Singh RD; Joshi DV; Patel HB; Mody SK
Vet World; 2016 Jan; 9(1):80-90. PubMed ID: 27051190
[TBL] [Abstract][Full Text] [Related]
49. FGFR4: A promising therapeutic target for breast cancer and other solid tumors.
Levine KM; Ding K; Chen L; Oesterreich S
Pharmacol Ther; 2020 Oct; 214():107590. PubMed ID: 32492514
[TBL] [Abstract][Full Text] [Related]
50. FGFR4 transmembrane domain polymorphism and cancer risk: a meta-analysis including 8555 subjects.
Xu W; Li Y; Wang X; Chen B; Wang Y; Liu S; Xu J; Zhao W; Wu J
Eur J Cancer; 2010 Dec; 46(18):3332-8. PubMed ID: 20638838
[TBL] [Abstract][Full Text] [Related]
51. Re-evaluating the FGFR4 (G388R) germline mutation in different cancers in Pakistani population.
Mansoor Q; Fayyaz S; Farooqi AA; Bhatti S; Ismail M
J Exp Ther Oncol; 2013; 10(3):215-7. PubMed ID: 24416997
[TBL] [Abstract][Full Text] [Related]
52. Germline variant FGFR4 p.G388R exposes a membrane-proximal STAT3 binding site.
Ulaganathan VK; Sperl B; Rapp UR; Ullrich A
Nature; 2015 Dec; 528(7583):570-4. PubMed ID: 26675719
[TBL] [Abstract][Full Text] [Related]
53. FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer.
Thussbas C; Nahrig J; Streit S; Bange J; Kriner M; Kates R; Ulm K; Kiechle M; Hoefler H; Ullrich A; Harbeck N
J Clin Oncol; 2006 Aug; 24(23):3747-55. PubMed ID: 16822847
[TBL] [Abstract][Full Text] [Related]
54. Loss of heterozygosity and DNA methylation affect germline fibroblast growth factor receptor 4 polymorphism to direct allelic selection in breast cancer.
Zhu X; Zheng L; Asa SL; Ezzat S
Am J Pathol; 2010 Dec; 177(6):2860-9. PubMed ID: 21037081
[TBL] [Abstract][Full Text] [Related]
55. Effects of FGFR4 G388R, V10I polymorphisms on the likelihood of cancer.
Peng T; Sun Y; Lv Z; Zhang Z; Su Q; Wu H; Zhang W; Yuan W; Zuo L; Shi L; Zhang LF; Zhou X; Mi Y
Sci Rep; 2021 Jan; 11(1):1373. PubMed ID: 33446698
[TBL] [Abstract][Full Text] [Related]
56.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
57.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
58.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
59.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
